[1] T. Noguchi, R. Shimazawa, K. Nagasawa, Y. Hashimoto, “Thalidomide and its analogues as cyclooxygenase inhibitors” Bioorganic & medicinal chemistry letters 12(7), 1043-1046, 2002.
[2] H. P. Koch, “4 Thalidomide and Congeners as Anti-inflammatory Agents” In Progress in medicinal chemistry 22, 165-242, 1985.
[3] V. Günzler, “Thalidomide in Human Immunodeficiency Virus (HIV) Patients” Drug safety, 7, 116-134, 2012.
[4] F. O. Kelsey, “Thalidomide update: Regulatory aspects” Teratology, 38, 221-226, 1988.
[5] S. K. Teo, K. E. Resztak, M. A. Scheffler, K. A. Kook, J. B. Zeldis, D. I. Stirling, S. D. Thomas, “Thalidomide in the treatment of leprosy” Microbes and infection, 4(11), 1193-1202, 2002.
[6] B. G. M. Durie, J-L Harousseau, J. S. Miguel, J. Bladé, B. Barlogie, K. Anderson, M. Gertz, M. Dimopoulos, J. Westin, P. Sonneveld, H. Ludwig, G. Gahrton, M. Beksac, J. Crowley, A. Belch, M. Boccadaro, I. Turesson, D. Joshua, D. Vesole, R. Kyle, R. Alexanian, G. Tricot, M. Attal, G. Merlini, R. Powles, P. Richardson, K. Shimizu, P. Tosi, G. Morgan, S. V. Rajkumar, “International uniform response criteria for multiple myeloma” Leukemia, 20(9), 1467-1473, 2006.
[7] E. R. Lepper, N. F. Smith, M. C. Cox, C. D. Scripture, W. D. Figg, “Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications” Current drug metabolism, 7(6), 677-685, 2006.
[8] S. K. Teo, D. I. Stirling, J. B. Zeldis, “Thalidomide as a novel therapeutic agent: new uses for an old product” Drug discovery today, 10(2), 107-114, 2005.
[9] N. Shibata, T. Yamamoto, T. Toru, “Synthesis of Thalidomide” Berlin, Heidelberg, 73-97, 2007.
[10] M. B. Kenyon, F. Browne, R. J. D'amato, “Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization” Experimental eye research, 64(6), 971-978, 1997.
[11] S. Wnendt, M. Finkam, W. Winter, J. Ossig, G. Raabe, K. Zwingenberger, “Enantioselective inhibition of TNF-α release by thalidomide and thalidomide-analogues” Chirality, 8(5), 390-396, 1996.
[12] R. C. Frederickson, I. H. Slater, W. E. Dusenberry, C. R. Hewes, G. T. Jones, R. A. Moore, “A comparison of thalidomide and pentobarbital - new methods for identifying novel hypnotic drugs” Journal of Pharmacology and Experimental Therapeutics, 203(1), 240-251, 1977. [13] S. Gao, S. Wang, R. Fan, J. Hu, “Recent advances in the molecular mechanism of thalidomide teratogenicity” Biomedicine & Pharmacotherapy, 127, 110114, 2020.
[14] N. S. Abdelwahab, N. W. Ali, M. M. Zaki, S. M. Z. Sharkawi, M. M. Abdelkawy, “Simultaneous Determination of Thalidomide and Dexamethasone in Rat Plasma by Validated HPLC and HPTLC With Pharmacokinetic Study” Journal of chromatographic science, 57(2), 130-138, 2019.
[15] R. Lugano, M. Ramachandran, A. Dimberg, “Tumor angiogenesis: causes, consequences, challenges and opportunities” Cell Mol Life Sci. 77, 1745–1770, 2020.
[16] Y. Shen, S. Li, X. Wang, M. Wang, Q. Tian, J. Yang, J. Wang, B. Wang, P. Liu, J. Yang, “Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin” J Exp Clin Cancer Res. 38, 427, 2019.
[17] T. Saunsbury, M. Harte, C. Venda-Nova, K. Patel, T. Hodgson, “Thalidomide therapy for refractory mucosal disease: benefit and risks over 10 years” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 131(4),e115-e116, 2021.
[18] X. Wang, Y. Shen, L. MengLv, X. Zhang, J. Yang, F. Wang, J. Yang, “Thalidomide suppresses breast cancer tumor growth by inhibiting tumor-associated macrophage accumulation in breast tumor-bearing” mice. Eur J Pharm Sci. 151, 105302, 2020.
[19] Z. Zhou, W. Mao, Y. Li, C. Qi, Y. He, “Myricetin inhibits breast tumor growth and angiogenesis by regulating VEGF/VEGFR2 and p38MAPK signaling pathways” Anat Rec (Hoboken) 302, 2186–2192, 2019.
[20] J. Tian, T. Song, H. Wang, W. Wang, Z. Zhang, R. Yan, “Thalidomide alleviates bone cancer pain by down-regulating expressions of NF-kappaB and GFAP in spinal astrocytes in a mouse model” Int J Neurosci.129, 896–903, 2019.
[21] V. A. F. S. N. Mussel, M. P. Ferreira, M. B. F. Marques, M. I. Yoshida, M. R. Almeida, B. L. Rodrigues, W. N. Mussel, “Physics, chemistry, and Hirshfeld surface analyses of gamma-irradiated thalidomide to evaluate behavior under sterilization doses” Journal of Pharmaceutical Analysis, 8(3), 194-201, 2018.
[22] B. Saikia, M. T. Mulvee, I. Torres-Moya, B. Sarma, J. W. Steed, “Drug Mimetic Organogelators for the Control of Concomitant Crystallization of Barbital and Thalidomide” Cryst. Growth Des. 20, 7989–7996, 2020.
[23] F. Kavousi, M. Goodarzi, D. Ghanbari, K. Hedayati, “Synthesis and characterization of a magnetic polymer nanocomposite for the release of metoprolol and aspirin” Journal of Molecular Structure. 1183, 324-330, 2019.
[24] C. Goosen, T. J. Laing, J. du Plessis, T. C. Goosen, G. L. Flynn, “Physicochemical Characterization and Solubility Analysis of Thalidomide and Its N-Alkyl Analogs” Pharmaceutical Research. 19, 13–19, 2002.
[25] W. Grzesiak and B. Brycki, “Synthesis, FTIR, C-NMR and Temperature-Dependent H-NMR Characteristics of Bis-naphthalimide Derivatives” Molecules. 17, 12427-124482112.
[26] A. Suksuwan, L. Lomlim, F. L. Dickert, R. Suedee, “Tracking the chemical surface properties of racemic thalidomide and its enantiomers using a biomimetic functional surface on a quartz crystal microbalance” J. APPL. POLYM. SCI. 42309, 1-14, 2015.
[27] S. C. Mei1, R. T. Wu, “The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma” Mol Cancer Ther. 7(8), 2405-2414, 2008.
[28] I. Ali, W. A. Wani, K. Saleem, M. F. Hseih, “Design and synthesis of thalidomide based dithiocarbamate Cu(II), Ni(II) and Ru(III)” Polyhedron. 56, 12, 134-143, 2013.